Hologic Reports $1.02 Billion Revenue and $254.6 Million Net Income in Q3 Fiscal 2025

Hologic, Inc. reported its financial results for the third quarter of fiscal 2025, revealing a total revenue of $1.02 billion, a slight increase from $1.01 billion in the same period last year. The company’s net income for the quarter was $254.6 million, compared to $244.0 million in the prior year, reflecting a 4.9% increase in profitability. The results were bolstered by strong performance in the Diagnostics and GYN Surgical segments, which saw revenue growth of 2.0% and 6.2%, respectively, while Breast Health revenues declined by 12.2% due to decreased sales of digital mammography systems.

In terms of operational changes, Hologic completed two significant acquisitions in fiscal 2025: Gynesonics for $340.7 million and Endomagnetics for $313.9 million. These acquisitions are expected to enhance Hologic's product offerings in the GYN Surgical and Breast Health segments, respectively. The company also recorded a $204 million impairment charge related to certain product lines, including Acessa and Mobidiag, which negatively impacted operating income in the current quarter.

Hologic's customer base and geographic reach remained stable, with the United States accounting for 74.3% of total revenues, while Europe contributed 14.5%. The company reported an increase in service revenues, which rose by 6.6% in the third quarter, driven by a growing installed base of digital mammography systems. However, the overall product revenue was affected by longer sales cycles and insufficient sales force execution in the Breast Health segment.

Looking ahead, Hologic anticipates continued growth in its Diagnostics and GYN Surgical segments, supported by the recent acquisitions and an expanding product portfolio. The company is also focused on managing its operational costs and improving efficiency, particularly in light of the restructuring efforts that resulted in the termination of 135 employees across various divisions. Hologic's management remains optimistic about the company's ability to navigate market challenges and capitalize on new opportunities in women's health.